On the heels of its recently released data in teens ages 12-15, Pfizer and BioNTech said they applied to the FDA to expand emergency use authorization for their COVID-19 vaccine to include that age group.
Meanwhile, real-world data from Israel suggested the South African variant may evade the companies’ vaccine to some extent. (Reuters)
Johnson & Johnson’s COVID-19 vaccine is in hot water, with the European Medicines Agency announcing an investigation into post-vaccination blood clots. Closer to home, vaccine sites in North Carolina, Colorado and Georgia temporarily shut down administration of the vaccine due to adverse reactions. (Bloomberg, CBS News)
